Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C

Background & Aims Several studies have reported that low doses of interferon can delay the development of hepatocellular carcinoma (HCC) and progression of chronic hepatitis C. We investigated the incidence of clinical events among participants of the Evaluation of PegIntron in Control of Hepati...

Full description

Saved in:

Bibliographic Details
Published in:	Gastroenterology (New York, N.Y. 1943) Vol. 140; no. 7; pp. 1990 - 1999
Main Authors:	Bruix, Jordi, Poynard, Thierry, Colombo, Massimo, Schiff, Eugene, Burak, Kelly, Heathcote, Elizabeth J.L, Berg, Thomas, Poo, Jorge–Luis, Mello, Carlos Brandao, Guenther, Rainer, Niederau, Claus, Terg, Ruben, Bedossa, Pierre, Boparai, Navdeep, Griffel, Louis H, Burroughs, Margaret, Brass, Clifford A, Albrecht, Janice K
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-06-2011
Subjects:	Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Biomarkers - blood Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - prevention & control Carcinoma, Hepatocellular - virology Clinical Trial Disease Progression Drug Administration Schedule EPIC 3 Program Europe Evaluation of PegIntron in Control of Hepatitis C Cirrhosis Program Female Gastroenterology and Hepatology Hepacivirus - genetics Hepatitis C, Chronic - complications Hepatitis C, Chronic - diagnosis Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - mortality Humans Hypertension, Portal - drug therapy Hypertension, Portal - virology Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Kaplan-Meier Estimate Liver Cancer Liver Cirrhosis - diagnosis Liver Cirrhosis - drug therapy Liver Cirrhosis - mortality Liver Cirrhosis - virology Liver Neoplasms - mortality Liver Neoplasms - prevention & control Liver Neoplasms - virology Male Middle Aged North America Patient Selection Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Proportional Hazards Models Prospective Studies Recombinant Proteins Risk Assessment Risk Factors RNA, Viral - blood South America Time Factors Treatment Outcome Viral Load Colchicine versus Peg-Intron Long-term Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Evaluation of PegIntron in Control of Hepatitis C Cirrhosis Program G Liver Cancer HR AFP esophagogastroduodenoscopy Evaluation of PegIntron in Control of Hepatitis C Cirrhosis SVR serious adverse event α-fetoprotein sustained virologic response hepatocellular carcinoma EGD HALT-C Clinical Trial AE EPIC 3 Program EPIC CI adverse event HCC genotype COPILOT SAE hazard ratio confidence interval
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!